Salicornia improves markers in patients after a stroke

Original paper reference.

  • Original title: Evaluating the Clinical Impact of a Polyphenol-Rich Extract from Salicornia ramosissima on Patients with Transient Ischemic Attack and Minor Stroke
  • Published in: Nutrients, 2024, Vol. 16, Artículo 4307
  • DOI: 10.3390/nu16244307

Paper abstract

This randomized, triple-blind, placebo-controlled clinical trial evaluated the safety and effects of a polyphenol-rich extract from hydroponically grown Salicornia ramosissima in 80 patients with a history of minor stroke or transient ischemic attack (TIA) over an 11-month period. Treatment consisted of daily capsules containing 1 g of the plant extract.

The results showed that the supplementation was safe and well tolerated. Clinical benefits were observed in the treated group, including:

  • Significant reduction in systolic and diastolic blood pressure, especially after physical exertion.
  • Sustained reduction in homocysteine levels, a marker of vascular risk.
  • Improvement in scores on the MoCA (Memory and Executive Function) cognitive test..
  • Trend toward improved kidney function (increased glomerular filtration rate).

The effects were more pronounced in women and in patients with a worse risk profile at baseline.

Key Points

  • Long-term (11-month), triple-blind, placebo-controlled clinical trial.
  • Participants: 80 patients post-TIA or minor stroke, at high vascular risk.
  • Treatment with a polyphenolic extract of hydroponic Salicornia ramosissima (1 g/day).
  • Significant reduction in resting and post-exercise blood pressure.
  • Sustained reduction of homocysteine to normal levels.
  • Improvement in memory and executive cognitive function on the MoCA test.
  • No serious adverse effects reported.
  • Positive trends in renal markers (creatinine, GFR) and lipid profile.
  • Relevant for secondary stroke prevention and neurovascular health.
Back to blog